Skip to Main Content
Our Commitment to Diversity

REPRESENTATIVE EXPERIENCE

Clayton E. Parker

Represented Kingswood Capital Partners, LLC as the lead book-runner in the initial public offering of SolarMax Technology, Inc. (NASDAQ: SMXT), a Riverside, California-based integrated solar and renewable energy company that engages in the solar business. Kingswood Capital Partners, LLC is one of the leading wealth management and investment banking firms headquartered in New York City, New York.
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$50 million PIPE investment in Cincinnati, Ohio-headquartered Workhorse Group Inc. (NASDAQ: WKHS).
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$30 million PIPE investment in Toronto, Canada-headquartered Cybin Inc. (NYSE: CYBN), (NEO: CYBN).
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$100 million PIPE investment in Miami, Florida-headquartered Veru Inc. (NASDAQ: VERU).
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$15 million PIPE investment in Texas-based Heart Test Laboratories, Inc. (NASDAQ: HSCS).
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, regarding a US$50 million PIPE investment in Connecticut-headquartered Chicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE).
Advised Chicago, Illinois-based Lincoln Park Capital, an investment group and asset management firm, on a US$10 million PIPE investment in Connecticut-based Aspira Women's Health Inc. (NASDAQ: AWH).
Represented QualTek USA, LLC in its acquisition of Broken Arrow Communications, Inc. ("BACOM"). QualTek USA, LLC provides communication infrastructure construction services.
Represented Enochian Biosciences, a Los Angeles-based biopharmaceutical company focused in identifying, developing, manufacturing, and commercializing gene-modified cell therapy, in its Registered Direct Offering of US$29 million of common stock.
Represented a public provider of genomic cancer testing services and its subsidiaries in connection with the refinancing of its revolving and term debt with a syndicate of financial institutions. 
Represented a client in a US$50 million registered direct offering.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel